Health-related quality of life in a Phase 2, randomized, placebo-controlled trial of the GABA(A)R modulator SAGE-217 in major depressive disorder

Authors
Category Primary study
JournalEUROPEAN NEUROPSYCHOPHARMACOLOGY
Year 2019
This article has no abstract
Epistemonikos ID: b4f7653066db6cac9f7ab0cc3fae864e6d3023cb
First added on: Feb 10, 2025